AzTrials
AzTrials

Type 2 Diabetes MellitusGIANTNCT00499824

GIANT: General Practitioner Implementation in Asia of Normoglycaemic Targets

A study testing Education of general practitioners on the IDF-WPR guidelines in people with Type 2 Diabetes Mellitus, run by International Diabetes Institute, Australia at 10 sites in 9 countries.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

To test whether the International Diabetes Federation - Western Pacific Region (IDF-WPR) Guidelines are more effective than standard practices in primary care (general practitioner) clinics for the management of type 2 diabetes mellitus (T2DM) in Asia. Read more about this study

Who is it for?
Ages 30 to 75 years
Conditions the study is for
Type 2 Diabetes Mellitus
What is being tested?
Education of general practitioners on the IDF-WPR guidelines
Could I receive a placebo?
No, everyone receives an active treatment
How many people
386 participants
Where
10 sitesin 9 countries
Study dates
Jan 2007to Feb 2009
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 30 to 75 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Men or women who are 30 to 75 years of age (inclusive) at Study Visit 1.
  • Clinical diagnosis of type 2 diabetes (defined according to IDF Guidelines) for a minimum of 6 months prior to Study Visit 1
  • Patients for whom the GP is the primary medical provider of diabetes care and for whom referral to another doctor for diabetes care is not anticipated within 3 months of Study Visit 1
  • Patients who give informed consent to participate.

Who cannot join

  • Patients with type 1 diabetes mellitus
  • Patients with any previous episode of ketoacidosis
  • Patients who required chronic use (>/= 6 months) of insulin at any time in the past, with the exception of females during pregnancy
  • Patients receiving insulin treatment at Study Visit 1 or within the previous 6 months, with the exception of patients who received short-term treatment (= 7 days) with insulin to maintain glycaemic control for an acute event (e.g. hospitalisation or medical procedure/intervention, infection or trauma).
  • Treatment with glucocorticoid at Study Visit 1 or within the previous 6 months, with the exception of topical or inhaled glucocorticoid
  • Females who are pregnant or considering pregnancy or stopping contraception within the course of the study
Show all 10Show fewer
  • Patients with end-stage renal disease, defined as glomerular filtration rate (GFR) by the MDRD (Modification of Diet in Renal Disease) formula < 15 ml/min/1.73 m2, or on renal replacement therapy with haemodialysis, peritoneal dialysis or renal transplant.
  • Patients with psychiatric disease, active drug or alcohol abuse or other cognitive impairment that may interfere with treatment compliance.
  • Receipt of any investigational drug within 30 days of Study Visit 1.
  • Patients receiving diabetes care from another doctor (specialist endocrinologist, general physician, or another GP) Other eligibility criteria considerations The HbA1c at entry for newly recruited patients will be monitored centrally. If there is a significant risk that more than 25% of the total study population will have a baseline HbA1c </= 6.5%, then recruitment of subsequent patients will be restricted to those with HbA1c > 6.5%.

Trial locations and contacts

10 sites in 9 countries.

10 sites in 9 countries

China2 sites
  • Department of Endocrinology & Metabolism, Peking University People's Hospital

    Beijing, 100044

  • Department of Medicine & Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong

    Shatin, Hong Kong

Other trials in China

Indonesia1 site
  • Diabetes and Nutrition Center, Dr. Soetomo Teaching Hospital - Airlangga University,

    Surabaya, 60286

Other trials in Indonesia

Malaysia1 site
  • School of Medicine and Health Sciences, Monash University House

    Johor Bahru, 80100

Other trials in Malaysia

Philippines1 site
  • Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of the Philippines College of Medicine

    Manila

Other trials in Philippines

Singapore1 site
  • Diabetes, Lipid and Endocrine Practice, Gleneagles Medical Centre

    Singapore, 258499

Other trials in Singapore

South Korea1 site
  • Department of Endocrinology & Metabolism, Kangnam St. Mary's Hospital, The Catholic University of Medicine

    Seoul

Other trials in South Korea

Taiwan1 site
  • Dept of Medical Research and Education, Taipei Veterans General Hospital,

    Taipei

Other trials in Taiwan

Thailand1 site
  • Diabetes and Endocrinology Unit, Department of Medicine, Rajavithi Hospital,

    Bangkok, 10400

Other trials in Thailand

Vietnam1 site
  • National Hospital of Endocrinology,

    Hanoi, Dongda District

Other trials in Vietnam

About this study

To test whether the International Diabetes Federation - Western Pacific Region (IDF-WPR) Guidelines are more effective than standard practices in primary care (general practitioner) clinics for the management of type 2 diabetes mellitus (T2DM) in Asia. A 12-month multinational multicentre prospective cluster randomisation clinical trial within a primary care setting, with 2 parallel treatment arms: diabetes management using IDF-WPR guidelines versus standard clinic practices. 400 subjects will be recruited from 100 sites (4 subjects per site) in ten Asian countries (China, Hong Kong, Indonesia, Korea, Malaysia, Philippines, Singapore, Taiwan, Thailand and Vietnam).

Read the detailed description

Description of intervention(s) / exposure and control treatment: This is a prospective multinational, multicentre, cluster-randomised study conducted within the primary care setting, with two parallel treatment arms: standard clinical practice versus education on diabetes management using International Diabetes Federation - Western Pacific Region (IDF-WPR) "Type 2 diabetes practical targets and treatments". The study duration will be 12 months.

100 General Practitioners (GPs) (10 per country) will be randomised to receive education on the IDF-WPR guidelines or to receive no trial-related education.

  • GPs in both groups will be required to recruit 4 of their own patients meeting the eligibility criteria. The complete entry criteria are detailed in a following section.
  • GPs in both groups will manage the recruited patients according to their own clinical judgement. Frequency of patient visits to the GP's clinic will be determined by the GP. All medication prescribed by the GPs should already be registered in the participating countries.
  • Blood sampling of patients will be required at Study Visit 1 (Screening/Baseline), Study Visit 2 (month 6) and Study Visit 3 (month 12).

The intervention will comprise an educational program on the guidelines for GPs, and will be carried out by the national coordinating centre in each country, based on a template provided by the international coordinating centre (International Diabetes Institute, Australia). The educational program for the GPs randomised to the intervention arm will:

  1. Combine didactic and interactive sessions.
  2. Involve opinion leaders, i.e. the national lead investigator
  3. Aim to resolve barriers to practical implementation of guidelines already identified from previous studies (e.g. discuss starting insulin)
  4. Present the evidence for the guidelines.
  5. Highlight any conflicts between the guidelines and local prescribing regulations, and confirm the need to follow the local prescribing regulations in these instances
  6. Involve an initial educational symposium and a follow-up continuing medical education symposium at 3 months

Organisational changes to improve guideline adherence for the study will include:

  1. Paper or electronic reminders of the guidelines will be sent to GPs every 3 months.
  2. Desktop reminders cards with key guideline algorithms.
  3. Insertion of a flowsheet (diabetes action plan) into the patient's medical notes by the study nurse (at the time of review of the practitioner's baseline HbA1c utilisation).

Patient-centred approaches to improve guideline adherence for the study will include:

  1. Encouragement and empowerment of patients to ask questions of the treating practitioners
  2. Provision of each patient with a "diabetes passport" to be held by the patient, to encourage discussion between the patient and practitioner and also recording of results of medical examinations. This will be provided at the baseline visit to the national coordinating centre.
Being tested
Education of general practitioners on the IDF-WPR guidelines
Keywords
Diabetes, Management guidelines, Efficacy
Medical subject headings
Diabetes Mellitus, Type 2, Diabetes Mellitus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Education of general practitioners on the IDF-WPR guidelinesBehavioural

    The intervention will comprise an educational program on the guidelines for GPs, and will be carried out by the national coordinating centre in each country, based on a template provided by the international coordinating centre (International Diabetes Institute, Australia). This will involve:

    an initial educational symposium and a follow-up continuing medical education symposium at 3 months; paper or electronic reminders of the guidelines sent to GPs every 3 months; desktop reminder cards with guideline algorithms; insertion of a flowsheet (diabetes action plan) into the patient's medical notes by the study nurse; provision of each patient with a "diabetes passport" to be held by the patient.

Study groups in NCT00499824
Study groupRoleWhat they receive
1ExperimentalMedical Practitioners who receive education on diabetes management following the guidelines of the International Diabetes Federation Western Pacific Region
Receives: Behavioral: Education of general practitioners on the IDF-WPR guidelines
2No interventionMedical practitioners who follow standard practice for management of their patients with type 2 diabetes

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in HbA1c from baseline in subjects with baseline HbA1c >/=6.5%

    Measured: 6 months

Secondary outcomes (1)
  1. HbA1c, FPG, BP, lipids; hypoglycemic events; health care use; number of GP HbA1c measurements; number of treatment escalations; adverse events; barriers to guideline implementation; determine if study patients are representative of GP's diabetic practice

    Measured: 6 & 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted11 Jul 2007 (estimated)
  2. Study startJan 2007
  3. Primary completionJan 2009
  4. Study completionFeb 2009

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
386 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00499824
Sponsor's protocol ID
IDI Project 4/2006
Acronym
GIANT
Status last verified
May 2010
First submitted
9 Jul 2007
Last updated
4 May 2010
Results posted
No
Data monitoring committee
No

Questions about this trial

What is this clinical trial studying?

A study testing Education of general practitioners on the IDF-WPR guidelines in people with Type 2 Diabetes Mellitus, run by International Diabetes Institute, Australia at 10 sites in 9 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 4 May 2010. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 10 sites in China, Indonesia, Malaysia, Philippines, Singapore and 4 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in HbA1c from baseline in subjects with baseline HbA1c >/=6.5% (time frame: 6 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 May 2010.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in